Journal articles on the topic 'Glucagon-like peptide analogues'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Glucagon-like peptide analogues.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Zhang, Yifan, and Wengen Chen. "Radiolabeled glucagon-like peptide-1 analogues." Nuclear Medicine Communications 33, no. 3 (March 2012): 223–27. http://dx.doi.org/10.1097/mnm.0b013e32834e7f47.
Full textGupta, Vishal. "Glucagon-like peptide-1 analogues: An overview." Indian Journal of Endocrinology and Metabolism 17, no. 3 (2013): 413. http://dx.doi.org/10.4103/2230-8210.111625.
Full textNilsson, Peter M. "Hemodynamic effects by glucagon-like peptide-1 receptor analogues." Journal of Hypertension 35, no. 5 (May 2017): 953–54. http://dx.doi.org/10.1097/hjh.0000000000001315.
Full textWilding, John P. H., and Kevin Hardy. "Glucagon-like peptide-1 analogues for type 2 diabetes." BMJ 342 (2011): d410. http://dx.doi.org/10.1136/bmj.d410.
Full textChun, Hyun-Ji, and Hyuk-Sang Kwon. "Clinical Efficacy of Glucagon Like Peptide-1 (GLP-1) Analogues." Journal of Korean Diabetes 14, no. 3 (2013): 125. http://dx.doi.org/10.4093/jkd.2013.14.3.125.
Full textGallwitz, Baptist. "Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus." Drugs 71, no. 13 (September 2011): 1675–88. http://dx.doi.org/10.2165/11592810-000000000-00000.
Full textDharmaraj, B. "A brief review on newer Glucagon like Peptide-1 analogues." International Journal of Preclinical and Clinical Research 1, no. 1 (December 21, 2020): 26–34. http://dx.doi.org/10.51131/ijpccr/v1i1.7.
Full textIacobellis, Gianluca. "Can epicardial fat glucagon-like peptide-1 receptor open up to the cardiovascular benefits of glucagon-like peptide-1 analogues?" Polish Archives of Internal Medicine 131, no. 3 (March 30, 2021): 224–25. http://dx.doi.org/10.20452/pamw.15904.
Full textJuul Holst, Jens. "Glucagon-like Peptide-1, A Gastrointestinal Hormone with a Pharmaceutical Potential." Current Medicinal Chemistry 6, no. 11 (November 1999): 1005–17. http://dx.doi.org/10.2174/092986730611220401163238.
Full textWilliams, David M., Matthew Staff, Stephen C. Bain, and Thinzar Min. "Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity." Endocrinology 18, no. 1 (2022): 43. http://dx.doi.org/10.17925/ee.2022.18.1.43.
Full textWelling, Mila Sofie, Cornelis J. de Groot, Lotte Kleinendorst, Bibian van der Voorn, Jan Steven Burgerhart, Eline S. van der Valk, Mieke M. van Haelst, Erica L. T. van den Akker, and Elisabeth F. C. van Rossum. "Effects of Glucagon-Like-Peptide-1 Analogue Treatment in Genetic Obesity." Journal of the Endocrine Society 5, Supplement_1 (May 1, 2021): A33—A34. http://dx.doi.org/10.1210/jendso/bvab048.065.
Full textSuntsov, Yury Ivanovich. "Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus." Diabetes mellitus 15, no. 1 (March 15, 2012): 6–9. http://dx.doi.org/10.14341/2072-0351-5971.
Full textBielka, Weronika, Agnieszka Przezak, Maria Salmanowicz, and Bolesław Banach. "Possibilities of using analogues of glucagon-like peptide-1 in various disease entities." Farmacja Polska 77, no. 1 (February 24, 2021): 48–55. http://dx.doi.org/10.32383/farmpol/133606.
Full textYellon, DerekM, MarynaV Basalay, and SeanM Davidson. "Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality?" Neural Regeneration Research 15, no. 10 (2020): 1852. http://dx.doi.org/10.4103/1673-5374.280313.
Full textArmstrong, Matthew J. "Glucagon-like peptide-1 analogues in nonalcoholic steatohepatitis: From bench to bedside." Clinical Liver Disease 10, no. 2 (August 2017): 32–35. http://dx.doi.org/10.1002/cld.650.
Full textClaus, Thomas H., Clark Q. Pan, Joanne M. Buxton, Ling Yang, Jennifer C. Reynolds, Nicole Barucci, Michael Burns, et al. "Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes." Journal of Endocrinology 192, no. 2 (February 2007): 371–80. http://dx.doi.org/10.1677/joe-06-0018.
Full textPrice, Samantha L., James S. Minnion, and Stephen R. Bloom. "Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats." Current Therapeutic Research 77 (December 2015): 111–15. http://dx.doi.org/10.1016/j.curtheres.2015.10.003.
Full textSu, Yunfang, Zijuan Zhang, Hao Li, Jinlian Ma, Limin Sun, Simai Shao, Zhenqiang Zhang, and Christian Hölscher. "A GLP-2 Analogue Protects SH-SY5Y and Neuro-2a Cells Against Mitochondrial Damage, Autophagy Impairments and Apoptosis in a Parkinson Model." Drug Research 71, no. 01 (October 6, 2020): 43–50. http://dx.doi.org/10.1055/a-1266-3263.
Full textXiao, Q., J. Giguere, M. Parisien, W. Jeng, S. A. St-Pierre, P. L. Brubaker, and M. B. Wheeler. "Biological Activities of Glucagon-Like Peptide-1 Analogues in Vitro and in Vivo." Biochemistry 40, no. 9 (March 2001): 2860–69. http://dx.doi.org/10.1021/bi0014498.
Full textKelly, Erik M., and Donald E. Cutlip. "Diabetes Drugs and Cardiovascular Event Reduction: A Paradigm Shift." US Cardiology Review 12, no. 1 (March 15, 2018): 46–50. http://dx.doi.org/10.15420/usc.2017:35:1.
Full textSawamura, Toshitaka, Shigehiro Karashima, Ai Ohmori, Kei Sawada, Mitsuhiro Kometani, Yoshiyu Takeda, and Takashi Yoneda. "Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Worsen after the Administration of Dulaglutide." Medicina 58, no. 2 (February 14, 2022): 289. http://dx.doi.org/10.3390/medicina58020289.
Full textKim, Ki-Suk, and Hyeung-Jin Jang. "Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors." Evidence-Based Complementary and Alternative Medicine 2015 (2015): 1–9. http://dx.doi.org/10.1155/2015/171742.
Full textKorbut, Anton Ivanovich, and Vadim Valerievich Klimontov. "Incretin-based therapy: renal effects." Diabetes mellitus 19, no. 1 (January 13, 2016): 53–63. http://dx.doi.org/10.14341/dm7727.
Full textZhou, Jinpei, Shuaijian Ni, Huibin Zhang, Hai Qian, Yushi Chi, Wenlong Huang, Lu Yu, Xiaowen Hu, and Wei Chen. "Synthesis and Bioactivity Evaluation of Dipeptidyl Peptidase IV Resistant Glucagon-like Peptide-1 Analogues." Protein & Peptide Letters 17, no. 10 (October 1, 2010): 1290–95. http://dx.doi.org/10.2174/092986610792231546.
Full textEbdrup, Björn H., Filip K. Knop, Pelle L. Ishoy, Egill Rostrup, Birgitte Fagerlund, Henrik Lublin, and Birte Glenthøj. "Poster #218 GLUCAGON-LIKE PEPTIDE-1 ANALOGUES AGAINST ANTIPSYCHOTIC-INDUCED OVERWEIGHT: POTENTIAL PHYSIOLOGICAL BENEFITS." Schizophrenia Research 136 (April 2012): S264. http://dx.doi.org/10.1016/s0920-9964(12)70789-2.
Full textHantouche, Christine M., Khalil M. Bitar, Georges M. Nemer, Mounir Y. Obeid, Lina N. Kadi, Asdghig H. Der-Boghossian, and Anwar B. Bikhazi. "Role of glucagon-like peptide-1 analogues on insulin receptor regulation in diabetic rat hearts." Canadian Journal of Physiology and Pharmacology 88, no. 1 (January 2010): 54–63. http://dx.doi.org/10.1139/y09-095.
Full textZalunin, I. A., A. S. Asrarkulova, and D. G. Kozlov. "Incretin Analogues in Therapy of Type 2 Diabetes and Obesity." Biotekhnologiya 37, no. 3 (2021): 53–64. http://dx.doi.org/10.21519/0234-2758-2021-37-3-53-64.
Full textLiu, Hongbin, Anthony E. Dear, Lotte B. Knudsen, and Richard W. Simpson. "A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules." Journal of Endocrinology 201, no. 1 (January 9, 2009): 59–66. http://dx.doi.org/10.1677/joe-08-0468.
Full textHolst, Jens Juul. "Pharmacology of GLP-1-based therapies." British Journal of Diabetes & Vascular Disease 8, no. 2_suppl (November 2008): S10—S18. http://dx.doi.org/10.1177/1474651408100523.
Full textSaraceni, Christine, and Tom L. Broderick. "Effects of Glucagon-Like Peptide-1 and Long-Acting Analogues on??Cardiovascular and Metabolic Function." Drugs in R & D 8, no. 3 (2007): 145–53. http://dx.doi.org/10.2165/00126839-200708030-00002.
Full textManavi, Mohammad Amin. "Neuroprotective effects of glucagon-like peptide-1 (GLP-1) analogues in epilepsy and associated comorbidities." Neuropeptides 94 (August 2022): 102250. http://dx.doi.org/10.1016/j.npep.2022.102250.
Full textFink-Jensen, Anders, and T. Vilsbøll. "Glucagon-like peptide-1 (GLP-1) analogues: A potential new treatment for alcohol use disorder?" Nordic Journal of Psychiatry 70, no. 8 (May 6, 2016): 561–62. http://dx.doi.org/10.1080/08039488.2016.1176252.
Full textELBANA, M.D., KHALED A. "Effect of Glucagon Like Peptide 1| (GLP1) Analogues on Obese Egyptians With and Without Diabetes." Medical Journal of Cairo University 87, September (September 1, 2019): 3205–8. http://dx.doi.org/10.21608/mjcu.2019.65613.
Full textEngeli, Stefan, and Jens Jordan. "Blood pressure effects of glucagon-like peptide 1 analogues and sodium glucose transporter 2 inhibitors." Current Opinion in Nephrology and Hypertension 23, no. 5 (September 2014): 468–72. http://dx.doi.org/10.1097/01.mnh.0000449846.91046.ac.
Full textBatista, Andre F., Victor Bodart-Santos, Fernanda G. De Felice, and Sergio T. Ferreira. "Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer’s and Parkinson’s Diseases." CNS Drugs 33, no. 3 (December 3, 2018): 209–23. http://dx.doi.org/10.1007/s40263-018-0593-6.
Full textAtila, Cihan, Thilo Burkard, Andrea Meienberg, Nica Jeanloz, Tanja Vukajlovic, Katja Bologna, Michelle Steinmetz, et al. "RF32 | PSUN59 Glucagon-Like Peptide-1 Analogues: A New Way to Quit Smoking? SKIP – a Randomised Controlled Study." Journal of the Endocrine Society 6, Supplement_1 (November 1, 2022): A261. http://dx.doi.org/10.1210/jendso/bvac150.536.
Full textIacobellis, Gianluca, Vladimir Camarena, David Sant, and Gaofeng Wang. "Human Epicardial Fat Expresses Glucagon-Like Peptide 1 and 2 Receptors Genes." Hormone and Metabolic Research 49, no. 08 (May 17, 2017): 625–30. http://dx.doi.org/10.1055/s-0043-109563.
Full textJi, Chenhui, Guo-Fang Xue, Guanglai Li, Dongfang Li, and Christian Hölscher. "Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer’s disease." Reviews in the Neurosciences 27, no. 1 (January 1, 2016): 61–70. http://dx.doi.org/10.1515/revneuro-2015-0021.
Full textGreen, BD, MH Mooney, VA Gault, N. Irwin, CJ Bailey, P. Harriott, B. Greer, FP O'Harte, and PR Flatt. "N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity." Journal of Endocrinology 180, no. 3 (March 1, 2004): 379–88. http://dx.doi.org/10.1677/joe.0.1800379.
Full textGÓRSKA, ALEKSANDRA, and MARCIN B. ARCISZEWSKI. "Distribution and function of glucagon-like peptide 1 (GLP-1) in the digestive tract of mammals and the clinical use of its analogues." Medycyna Weterynaryjna 76, no. 07 (2023): 6374–2023. http://dx.doi.org/10.21521/mw.6374.
Full textL A, Maheswary, Dr Silvia Navis, Anusree S, and Dr Prasobh G.R. "Role of Glucagon-Like Peptide-1 Analogues on Obesity and Type-II Diabetes Mellitus: A Review." International Journal of Pharmaceutical Sciences Review and Research 64, no. 2 (October 20, 2020): 102–8. http://dx.doi.org/10.47583/ijpsrr.2020.v64i02.017.
Full textHan, Jing, Yue Huang, Xinyu Chen, Feng Zhou, Yingying Fei, and Junjie Fu. "Rational design of dimeric lipidated Xenopus glucagon-like peptide 1 analogues as long-acting antihyperglycaemic agents." European Journal of Medicinal Chemistry 157 (September 2018): 177–87. http://dx.doi.org/10.1016/j.ejmech.2018.07.072.
Full textPizzoferrato, Marco, Pierluigi Puca, Sara Ennas, Giovanni Cammarota, and Luisa Guidi. "Glucagon-like peptide-2 analogues for Crohn’s disease patients with short bowel syndrome and intestinal failure." World Journal of Gastroenterology 28, no. 44 (November 28, 2022): 6258–70. http://dx.doi.org/10.3748/wjg.v28.i44.6258.
Full textRuyatkina, Lyudmila Alexandrovna, and Maxim Sorokin. "Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance." Diabetes mellitus 20, no. 2 (June 20, 2017): 142–50. http://dx.doi.org/10.14341/7875.
Full textCarydias, Elisabeth, Andoneta Tasho, Chara Kani, Flora Bacopoulou, Charikleia Stefanaki, and Sophia L. Markantonis. "Systematic Review and Meta-Analysis of the Efficacy and Safety of Metformin and GLP-1 Analogues in Children and Adolescents with Diabetes Mellitus Type 2." Children 9, no. 10 (October 18, 2022): 1572. http://dx.doi.org/10.3390/children9101572.
Full textBratilova, E. S., V. A. Kachnov, V. V. Tyrenko, I. S. Zheleznyak, D. V. Cherkashin, S. V. Kushnarev, and A. D. Sobolev. "Fat depot of the heart: contribution to the development of cardiovascular diseases, visualization methods and the possibilities of it’s correction." Bulletin of the Russian Military Medical Academy 22, no. 3 (December 15, 2020): 211–16. http://dx.doi.org/10.17816/brmma50562.
Full textLi, X. n., H. m. Bu, X. h. Ma, Sh Lu, Sh Zhao, Y. l. Cui, and J. Sun. "Glucagon-like Peptide-1 Analogues Inhibit Proliferation and Increase Apoptosis of Human Prostate Cancer Cells in vitro." Experimental and Clinical Endocrinology & Diabetes 125, no. 02 (December 22, 2016): 91–97. http://dx.doi.org/10.1055/s-0042-112368.
Full textWiśniewski, Kazimierz, Javier Sueiras-Diaz, Guangcheng Jiang, Robert Galyean, Mark Lu, Dorain Thompson, Yung-Chih Wang, et al. "Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance." Journal of Medicinal Chemistry 59, no. 7 (March 25, 2016): 3129–39. http://dx.doi.org/10.1021/acs.jmedchem.5b01909.
Full textCary, Brian P., Marlies V. Hager, and Samuel H. Gellman. "Impact of Substitution Registry on the Receptor‐Activation Profiles of Backbone‐Modified Glucagon‐like Peptide‐1 Analogues." ChemBioChem 20, no. 22 (September 20, 2019): 2834–40. http://dx.doi.org/10.1002/cbic.201900300.
Full textXiao, Jianzhong, and Wenying Yang. "Weight Loss Is Still an Essential Intervention in Obesity and its Complications: A Review." Journal of Obesity 2012 (2012): 1–6. http://dx.doi.org/10.1155/2012/369097.
Full text